Pelthos Therapeutics is spending nearly two dollars to generate every dollar of ZELSUVMI revenue, and that math is the entire strategic story right now. Q1 2026 net product revenue hit $10.7 million — a clean 17% sequential gain — but SG&A of $21.1 million means the company is burning roughly $10 million per quarter just to sustain a single-product launch in dermatology. The Horizon Technology Finance term loan, drawn at $30 million in January, leaves $32 million in cash on hand. That runway is tight for a company planning to add two more products — XEPI and XEGLYZE — to its commercial infrastructure within the next 12 months.
The unit economics do carry genuine signal. Dispensed units rose 25% quarter over quarter to 7,884, and April alone contributed 3,776 units, implying Q2 is tracking at an annualized pace that could push full-year revenue well above $50 million if the trajectory holds. Prescriber breadth expanded to 4,867 unique writers since launch, and the sales force grew from 50 to 64 territory managers during Q1 — the direct cause of the $1.5 million jump in commercial spend. That’s a deliberate investment in penetration depth, not inefficiency, and the prescriber-per-rep ratio remains manageable. The question is whether the revenue curve bends sharply enough before the debt service compounds further. Interest expense nearly doubled sequentially to $2.4 million, and the $5.2 million fair-value swing on convertible notes adds P&L noise that obscures the underlying cash burn.
The three-product commercialization plan is simultaneously the bull case and the liquidity trap. XEPI, a topical antibiotic for impetigo, and XEGLYZE, a head lice treatment, are both differentiated assets in small but defensible dermatology niches. Layering them onto an existing sales infrastructure of 64 reps is operationally logical — marginal cost of adding products to an established call universe is far lower than standing up a second salesforce. But manufacturing, regulatory, and royalty expenses already jumped $1.2 million and $0.3 million respectively in Q1, suggesting pre-launch costs for those franchises are already flowing through the income statement. Pelthos is front-loading expenses against revenue that doesn’t arrive until mid-2027.
The single number worth tracking in Q2 results is not total revenue but the dispensed-units-per-prescriber ratio. If that figure climbs meaningfully above the current implied average of roughly 1.6 units per prescriber, it signals that ZELSUVMI is becoming a reflex prescription rather than a trial. That shift — repeat prescribing behavior — is what converts a launch trajectory into a defensible commercial position, and it’s the only internal metric that justifies the capital structure Pelthos has built around this franchise.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
